Zma 2013 conferinta de presa

Customer & Market Insight Manager at real,- hypermarket romania
May. 7, 2013
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
Zma 2013 conferinta de presa
1 of 18

More Related Content

More from Ana-Maria Tatucu

Beauty barometer cv-2016-onlineBeauty barometer cv-2016-online
Beauty barometer cv-2016-onlineAna-Maria Tatucu
Apivita Bee radiant comunicat de presa 2015Apivita Bee radiant comunicat de presa 2015
Apivita Bee radiant comunicat de presa 2015Ana-Maria Tatucu
Artdeco colors spring summer 2015 eng.pdf press release fashion colors spring...Artdeco colors spring summer 2015 eng.pdf press release fashion colors spring...
Artdeco colors spring summer 2015 eng.pdf press release fashion colors spring...Ana-Maria Tatucu
Rosaliac CC cream La Roche PosayRosaliac CC cream La Roche Posay
Rosaliac CC cream La Roche PosayAna-Maria Tatucu
Herbalife-SkinHerbalife-Skin
Herbalife-SkinAna-Maria Tatucu
Beautybarometer presentation nov2014-onlineversionBeautybarometer presentation nov2014-onlineversion
Beautybarometer presentation nov2014-onlineversionAna-Maria Tatucu

Zma 2013 conferinta de presa

Editor's Notes

  1. Slide F.14 Asthma is a chronic inflammatory disease of the airways. 1 Chronically inflamed airways become hyperresponsive to a variety of stimuli and obstructed by bronchoconstriction, edema, excess mucus production, and infiltrating inflammatory cells. 1,2 The resulting airflow limitation leads to the characteristic symptoms of asthma: recurrent episodes of wheezing, breathlessness, chest tightness, and cough, particularly at night or in the early morning. 2 Chronic, active inflammation is present and central to the disease in all patients with asthma, even when no symptoms are evident. 2 Therefore, the goal of asthma treatment is to suppress airway inflammation and thereby modify disease progression. 2 Accordingly, guidelines issued by the Global Initiative for Asthma (GINA) recommend the use of anti-inflammatory agents for all severities of persistent asthma, from mild to severe. 1 1/NIH 2005, p 4, ¶4, L1   1/NIH 2005, p 4, ¶4, L1-5   2/Bjermer, p 704, C2, L3-9   2/Bjermer, p 704, C1, ¶7, L1-6 2/Bjermer, p 704, C1, ¶8, L1-2, C2, L1-3   2/Bjermer, p 704, C2, ¶1, L4-8   1/NIH 2005, p 20, Table; p 21, Table References National Institutes of Health. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention: A Pocket Guide for Physicians and Nurses . Updated 2005. Publication No. 02-3659. Bethesda, MD: National Institutes of Health, 2005. Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir Med 2001;95:703 – 719. 1/NIH 2005, p 4, ¶4, L1   1/NIH 2005, p 4, ¶4, L1-5   2/Bjermer, p 704, C2, L3-9   2/Bjermer, p 704, C1, ¶7, L1-6 2/Bjermer, p 704, C1, ¶8, L1-2, C2, L1-3   2/Bjermer, p 704, C2, ¶1, L4-8   1/NIH 2005, p 20, Table; p 21, Table